Similarly, circulating and hepatic CXCL16 was reportedly increased in NAFLD patients [166]; furthermore, CXCR6+ NKT cells [167] and autoaggresive CXCR6+ CD8+ T cells [168] (CXCR6 is the receptor of CXCL16) have been identified in the liver of MCD diet-fed mice and choline-deficient-HFD-fed mice, respectively, to promote inflammation, hepatic fibrosis, and possibly NASH-associated HCC. Here, CXCL16 is linked to metabolic dysfunction-associated steatotic liver disease.